About Janux Therapeutics, Inc.
https://www.januxrx.comJanux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.
CEO
David Alan Campbell
Compensation Summary
(Year 2022)
ETFs Holding This Stock
Summary
Showing Top 3 of 124
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
B of A Securities
Buy
HC Wainwright & Co.
Buy
Clear Street
Buy
Stifel
Buy
Barclays
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:11.19M
Value:$158M
FMR LLC
Shares:9.06M
Value:$127.87M
JANUS HENDERSON GROUP PLC
Shares:4.7M
Value:$66.38M
Summary
Showing Top 3 of 185
About Janux Therapeutics, Inc.
https://www.januxrx.comJanux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $10M ▲ | $44.75M ▼ | $-24.31M ▲ | -243.13% ▼ | $-0.39 ▲ | $-23.81M ▲ |
| Q2-2025 | $0 | $45.12M ▲ | $-33.86M ▼ | 0% | $-0.55 ▼ | $-44.58M ▼ |
| Q1-2025 | $0 | $34.9M ▲ | $-23.51M ▼ | 0% | $-0.38 ▼ | $-34.38M ▼ |
| Q4-2024 | $0 ▼ | $29.02M ▼ | $-20.22M ▲ | 0% ▲ | $-0.36 ▲ | $-28.51M ▲ |
| Q3-2024 | $439K | $36.28M | $-28.06M | -6.39K% | $-0.51 | $-35.33M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $988.99M ▼ | $1.02B ▼ | $48.21M ▲ | $976.55M ▼ |
| Q2-2025 | $996.01M ▼ | $1.03B ▼ | $41.7M ▲ | $990.52M ▼ |
| Q1-2025 | $1.01B ▼ | $1.05B ▼ | $38.3M ▼ | $1.01B ▼ |
| Q4-2024 | $1.03B ▲ | $1.06B ▲ | $38.73M ▼ | $1.02B ▲ |
| Q3-2024 | $658.03M | $695.02M | $38.91M | $656.1M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-24.31M ▲ | $-12.86M ▲ | $8.31M ▲ | $493K ▼ | $-4.06M ▲ | $-12.95M ▲ |
| Q2-2025 | $-33.86M ▼ | $-23.81M ▼ | $1.56M ▲ | $954K ▲ | $-21.3M ▲ | $-24.29M ▼ |
| Q1-2025 | $-23.51M ▼ | $-17.02M ▼ | $-340.39M ▼ | $554K ▼ | $-356.86M ▼ | $-17.39M ▼ |
| Q4-2024 | $-20.22M ▲ | $-16.73M ▼ | $33.93M ▲ | $386.65M ▲ | $403.85M ▲ | $-16.77M ▼ |
| Q3-2024 | $-28.06M | $-2.23M | $12.67M | $1.65M | $12.09M | $-2.26M |
CEO
David Alan Campbell
Compensation Summary
(Year 2022)
ETFs Holding This Stock
Summary
Showing Top 3 of 124
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
B of A Securities
Buy
HC Wainwright & Co.
Buy
Clear Street
Buy
Stifel
Buy
Barclays
Overweight
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:11.19M
Value:$158M
FMR LLC
Shares:9.06M
Value:$127.87M
JANUS HENDERSON GROUP PLC
Shares:4.7M
Value:$66.38M
Summary
Showing Top 3 of 185